

Nepal Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal												
2. Grant number(s): 19-NPL-25d-X; 14-NPL-08h-Y; 18-NPL-08p-Y												
3. Date of Decision Letter: 27 March 2019												
4. Date of the Partnership Framework Agreement: 22 August 2014												
5. Programme title: NVS, IPV routine												
6. Vaccine type: Inactivated Polio Vaccine (IPV)												
7. Requested product presentation and formulation of vaccine¹: Fractional use of Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID												
8. Programme duration²: 2014 - 2019												
<p>9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i></p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 20%;">2014-2018</th> <th style="width: 20%;">2019</th> <th style="width: 30%;">Total³</th> </tr> </thead> <tbody> <tr> <td>Routine Programme (US\$)</td> <td style="text-align: right;">3,544,749⁴</td> <td style="text-align: right;">742,000</td> <td style="text-align: right;">4,286,749</td> </tr> <tr> <td>Total Budget (US\$)</td> <td style="text-align: right;">3,544,749</td> <td style="text-align: right;">742,000</td> <td style="text-align: right;">4,286,749</td> </tr> </tbody> </table>		2014-2018	2019	Total ³	Routine Programme (US\$)	3,544,749 ⁴	742,000	4,286,749	Total Budget (US\$)	3,544,749	742,000	4,286,749
	2014-2018	2019	Total ³									
Routine Programme (US\$)	3,544,749 ⁴	742,000	4,286,749									
Total Budget (US\$)	3,544,749	742,000	4,286,749									
<p>10. Vaccine introduction grant (in US\$):</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 50%;">2014</th> <th style="width: 50%;">2018</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">462,000 disbursed on 25 July 2014</td> <td style="text-align: center;">514,078 disbursed on 26 January 2018</td> </tr> </tbody> </table>	2014	2018	462,000 disbursed on 25 July 2014	514,078 disbursed on 26 January 2018								
2014	2018											
462,000 disbursed on 25 July 2014	514,078 disbursed on 26 January 2018											
<p>11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)⁵</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 50%;"></th> <th style="width: 25%;">2014-2018</th> <th style="width: 25%;">2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccines to be purchased with Gavi funds</td> <td></td> <td></td> </tr> <tr> <td>IPV Routine Programme (doses)</td> <td></td> <td style="text-align: right;">209,900</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td style="text-align: right;">3,544,749</td> <td style="text-align: right;">742,000</td> </tr> </tbody> </table>		2014-2018	2019	Number of vaccines to be purchased with Gavi funds			IPV Routine Programme (doses)		209,900	Annual Amounts (US\$)	3,544,749	742,000
	2014-2018	2019										
Number of vaccines to be purchased with Gavi funds												
IPV Routine Programme (doses)		209,900										
Annual Amounts (US\$)	3,544,749	742,000										

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2014 to 2019.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

12. Procurement agency: UNICEF	
13. Self-procurement: Not applicable	
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Nepal is encouraged to contribute to vaccine and/or supply costs for IPV.	
15. Operational support for catch-up campaigns: Not applicable	
16. Additional reporting requirements:	
	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. <p>Countries shall report the actual switch date in the first renewal request following the actual implementation.</p>	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Country shall provide the following clarifications to Gavi: Not applicable	
18. Other conditions:	
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Nepal envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Nepal.</p>	

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
27 March 2019